Biovail opens new front in Andrx diltiazem dispute
Executive Summary
"As a result of preliminary testing to date, Biovail has given notice to Andrx that its Cartia XT product may be infringing the agreed upon dissolution specifications" contained in the Stipulation and Agreement originally signed between Andrx and Aventis. Cartia XT is a generic version of Cardizem CD; Biovail acquired rights to the Aventis brand in January (1"The Pink Sheet" Jan. 8, p. 21). Andrx launched Cartia XT after settling a patent dispute with Aventis; the settlement is the subject of a pending Federal Trade Commission administrative action
You may also be interested in...
Andrx Generic Tiazac Open For Approval; Court Lifts 30-Month Stay
The stay of approval on Andrx' generic version of Biovail/Forest's Tiazac (diltiazem) will be lifted Sept. 27, Miami federal court Judge William Dimitrouleas ruled Sept. 19.
Andrx Generic Tiazac Open For Approval; Court Lifts 30-Month Stay
The stay of approval on Andrx' generic version of Biovail/Forest's Tiazac (diltiazem) will be lifted Sept. 27, Miami federal court Judge William Dimitrouleas ruled Sept. 19.
Biovail Buys Old Cardizem Name For New Diltiazem Product
Biovail's purchase of Aventis' Cardizem line will allow the company to market its once-daily diltiazem under an established brand name.